Teva

20 stories about Teva
קור שולץ מנכ"ל טבע 9.11.19

The U.S. Opioid Abuse Lawsuits Are Political, Says Teva CEO

19.02.20|Sophie Shulman
Teva’s stock fluctuation is not the result of wrongdoing regarding the U.S. opioid abuse epidemic, but rather something born of the creativity of lawyers, Kåre Schultz said Wednesday at the company’s annual press conference in Tel Aviv
מוסף תרופה תרופות בית מרקחת

Teva Israel to Stop Distribution of Weight Loss Drug Amid Cancer Concerns

16.02.20|Lilach Baumer
On Thursday, the manufacturer of Belviq weight loss drug, Eisai, announced it was withdrawing the drug from the U.S. market after a five-year trial found it increased risk of cancer by 0.6%
קור שולץ מנכ"ל טבע 9.11.19

Teva’s Small Print Gives Rise to Optimism

13.02.20|Sophie Shulman
The improvement CEO Kåre Shultz promised is not immediately evident in the drugmaker’s forecast for 2020, but a closer look shows Teva’s new brand drugs are starting to live up to their promise
קור שולץ מנכ"ל טבע 9.11.19

Teva Receives FDA Approval for Migraine Autoinjector

29.01.20|Sophie Shulman
Teva’s anti-migraine injection was approved in late 2018 but struggled to establish a market share due to both Amgen and Eli Lilly offering a similar drug with an autoinjector
קור שולץ מנכ"ל טבע 9.11.19

Teva Fights Muddy Reputation With Positive Report

23.01.20|Sophie Shulman
Calcalist obtained a report commissioned by the Israeli drugmaker that details its economic contribution to the countries in which it operates
רופא מומחה קופת חולים קופות חולים מחלה

Premature Ejaculation: There’s an App, and a Patch, For That

01.12.19|Navit Zomer and Adi Pick
Virility develops a single-use electrified skin patch that, when placed on the perineum, can delay premature ejaculation by delivering neuromuscular stimulation
קור שולץ מנכ"ל טבע 9.11.19

Teva Faces U.S. Criminal Probe on Opioid-Related Distribution, Report Says

27.11.19|CTech
The Israeli drugmaker is one of six companies to receive subpoenas from federal investigators, the Wall Street Journal reported Tuesday
מטה חברת טבע תרופות

Teva in Talks With U.S. DoJ to End Price-Fixing Probe, Report Says

26.11.19|CTech
The Israeli drugmaker, along with several other companies investigated in the matter, have been holding talks on the subject for the past six months, Bloomberg reported
קור שולץ מנכ"ל טבע 9.11.19

Teva Raises $2.1 Billion in Debt Tender Offer

20.11.19|Sophie Shulman
Teva originally aimed to raise $1.5 billion, to redeem previous debentures it raised to finance the $40.5 billion acquisition of Actavis in 2016
אתר טבע כפר סבא

Teva’s Israeli Plant Receives FDA Stamp of Approval for Migraine Drug Manufacturing

17.11.19|Navit Zomer
The Israeli drugmaker’s manufacturing facility in Kfar Saba, already experienced with manufacturing cash cow Copaxone, will oversee the process of filling the syringes with the biological drug and also conduct quality control tests
מטה חברת טבע תרופות

Teva Up 25% on NYSE Since Third Quarter Reports

17.11.19|Sophie Shulman
The Israeli drugmaker closed 8.74% up on Friday after a Cleveland County District judge reduced the fine placed on Johnson and Jonhson in Oklahoma by $107 million, citing a math error made in the original ruling
קור שולץ מנכ"ל טבע 9.11.19

Teva Is Pulling an Ace From its Sleeve in its Attempt to Reinvent Itself

11.11.19|Uri Tal-Tene
With one anti-cancer biosimilar launching this week and another expected to hit the market soon, Teva could be creating a new growth engine worth hundreds of millions of dollars a year
קור שולץ מנכ"ל טבע 9.11.19

Teva Announces $1.5 Billion Debt Tender Offer

10.11.19|Sophie Shulman
On Thursday, the Israeli drugmaker published its third quarter reports for 2019, reporting it had cut down its net debt to $25.7 billion
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva Quarterly Report Meets Analyst Expectations

07.11.19|Sophie Shulman
The Israeli drugmaker’s revenues dropped 6% in the third quarter of 2019 to $4.26 billion. Debt dropped by $1.8 billion to $26.9 billion
מטה חברת טבע תרופות

Teva Overcomes One Hurdle, Many Still Ahead

23.10.19|Hezi Sternlicht
The Israeli drugmaker announced on Monday two major achievements regarding the opioid abuse lawsuits against it; but even without taking into consideration its additional legal complications, the settlements it has reached will severely strain its resources
מטה חברת טבע תרופות

Teva Announces $23.25 Billion Opioid Abuse Settlement Agreement

22.10.19|Lilach Baumer
Teva announced on Monday a settlement with both Cuyahoga and Summit counties of Ohio, averting the trial scheduled for later that day, and an agreement in principle for a global settlement framework
מטה חברת טבע תרופות

Teva Consortium Fails to Reach Opioid Abuse Settlement, Report Says

20.10.19|CTech
A $50 billion offer made last week by Teva and the three largest drug distributors in the U.S. does not seem to have panned out, Reuters reported Friday
מטה חברת טבע תרופות

Teva Part of $50 Billion Opioid Settlement Deal, Report Says

17.10.19|Hezi Sternlicht
Teva, a second drugmaker, and the three largest drug distributors in the U.S. have agreed with multiple states on a settlement framework ahead of Monday’s trial, the New York Times reported Thursday
אתר טבע כפר סבא

Teva Makes $15 Billion Settlement Offer in U.S. Opioid Case, Report Says

16.10.19|Hezi Sternlicht
The Israeli drugmaker and several other drug distributors are set to face around 2,500 lawsuits related to the U.S. opioid abuse epidemic in just a week at a Cleveland, Ohio federal court
מטה חברת טבע תרופות

Judge Rejects Teva’s Request to Be Tried Separately in U.S. Opioid Case, Report Says

13.10.19|CTech
Teva made a last minute attempt to be tried separately in opioid abuse damages case set to be held on October 21 in federal court in Cleveland, Ohio